Bailitianheng (688506.SH) announced on June 21 that in order to further support the company's international business development and better utilize domestic and overseas financing platforms, it will solidify the company's capital reserve for rapid development, support the global development of the company's many innovative products in Europe, America, Japan and other international markets, vigorously promote the implementation of the company's strategy to become a multinational pharmaceutical enterprise (MNC) with global leading advantages in the field of oncology drug use, and intends to issue shares overseas (H-shares) and list on the main board of the Hong Kong Stock Exchange (HKEX). The company will choose the appropriate timing and issuance window to complete the issuance of H-shares and listing within the valid period of the shareholder meeting resolution.